切换至 "中华医学电子期刊资源库"
高级检索
中华介入放射学电子杂志

中华介入放射学电子杂志 ›› 2014, Vol. 02 ›› Issue (03) : 65 -67. doi: 10.3877/cma.j.issn.2095-5782.2014.03.018

所属专题： 经典病例； 经典病例； 文献；

病例报告

个案报道：三维适形消融治疗肝左叶胆管细胞癌1例
扈彩霞1, 郑加生1,†(), 孙斌1   
  1. 1. 100069　首都医科大学附属北京佑安医院介入中心
  • 收稿日期:2013-06-05 出版日期:2014-08-01
  • 通信作者: 扈彩霞, 郑加生

3-Dimension Conformal Technology Guided Radiofrequency Ablation of liver’s left lobe for Intrahepatic Cholangiocarcinoma: A Case Report

Jiasheng Zheng1,†, Caixia Hu1(), Bin Sun1   

  1. 1. Center of Minimally Invasive Intervention, Beijing You-an Hospital, Capital Medical University, Beijing 100069, P.R.China
  • Received:2013-06-05 Published:2014-08-01
  • Corresponding author: Jiasheng Zheng, Caixia Hu
  • About author:
    Correspondence to: Dr Jiasheng Zheng, Center of Minimally Invasive Intervention, Beijing You-an Hospital, Capital Medical University, Beijing 100069, P.R.China;
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

扈彩霞, 郑加生, 孙斌. 个案报道：三维适形消融治疗肝左叶胆管细胞癌1例[J/OL]. 中华介入放射学电子杂志, 2014, 02(03): 65-67.

Jiasheng Zheng, Caixia Hu, Bin Sun. 3-Dimension Conformal Technology Guided Radiofrequency Ablation of liver’s left lobe for Intrahepatic Cholangiocarcinoma: A Case Report[J/OL]. Chinese Journal of Interventional Radiology(Electronic Edition), 2014, 02(03): 65-67.

肝细胞癌和胆管细胞癌是常见的两种肝脏肿瘤。不能切除的未经治疗的胆管细胞癌患者预后差，尤其是发生门静脉受侵的患者。目前胆管细胞癌尚无有效的治疗手段。射频消融（radiofrequency ablation，RFA)在不能进行手术切除的肝恶性肿瘤治疗中发挥重要作用，在此，我们报道成功运用射频消融治疗伴有门静脉癌栓的肝内胆管细胞癌一例，该患者共计存活26个月。

关键词: 肝内胆管细胞癌, 肿瘤栓子, 射频消融

Hepatocellular carcinoma and cholangiocarcinoma are the two most common malignant liver tumors.The prognosis for patients with untreated unresectable cholangiocarcinoma is depressed,especially to the patient with invasion in the portal vein. It has no effective treatment presently. Radiofrequency ablation (RFA) plays an importmant role in the treatment of unresectable liver tumors.It is considered a viable alternative to surgery for inoperable patients. Here,we report the successful use of CT- guided RFA in a patient with intrahepatic Cholangiocarcinoma with invasion in the portal vein.The patient survived for 26 months.

Key words: intrahepatic cholangiocarcinoma, tumor thrombus, radiofrequency ablation
Figure 1. Contrast-enhanced CT images of 56-year-old woman with intrahepatic cholangiocarcinoma. It revealed left lobe of liver’s lesions and left branch of portal vein was invasive.
Figure 2. Original magnifications, ×200 and ×400,A,B. Hematoxylin and eosin staining showed morphologic evaluation of intrahepatic cholangiocarcinoma obtained from the patient.
Figure 3. Immunohistochemistry for Hepatocyte(C) and CK-19 (D)in the patient. Hepatocyte staining showed that cancer cells were generally negative. A diffusely positive staining was observed in the tumoral cells for CK-19.
Figure 4. CT guided percutaneous RFA. RFA of the tumor thrombus in the left portal vein and the whole left lobe of liver.
Figure 5. Follow up contrast-enhanced CT images after 6 months from the last time of RFA.The patient’s left lobe of liver was ablated completely
1
Park J,Kim MH,Kim KP, et al. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 2009;3 :298-305
2
Burger I,Hong K,Schulick R, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol2005 ;16 :353-361
3
Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353-1357.
4
Taylor-Robinson SD,Toledano MB,Arora S, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales, 1968-1998. Gut. 2001;48:816-820.
5
Davila JA,El-Serag HB. Cholangiocarcinoma: the "other " liver cancer on the rise. Am J Gastroenterol. 2002;97:3199-3200.
6
de Groen PC,Gores GJ,LaRusso NF, et al. Biliary tract cancers. N Engl J Med. 1999;341:1368-1378.
7
Park J,Kim MH,Kim KP, et al. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 2009;3 :298-305
8
Burger I,Hong K,Schulick R, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol2005 ;16 :353-361
9
Nakeeb A,Tran KQ,Black MJ, et al. Improved survival in resected biliary malignancies. Surgery 2002;132 :555-563
10
Ben-Menachem T. Risk factors for cholangiocarcinoma. Eur. J. Gastroenterol. Hepatol.2007, 19, 615–617
11
Blechacz B. R., Gores G. J.Cholangiocarcinoma. Clin. Liver Dis. 2008,12, 131–150,
12
El-Serag H. B., Engels E. A., Landgren O., Chiao E., Henderson L., Amaratunge H. C., Giordano T. P.Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. Hepatology,2009, 49, 116–123
13
Aljiffry M,Walsh MJ,Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990–2009. World J Gastroenterol 2009;15 :4240-4262
14
De Baere T,Deschamps F,Briggs P, et al. Hepatic malignancies: percutaneous radiofrequency ablation during percutaneous portal or hepatic vein occlusion. Radiology 2008;248 :1056-1066
15
Cho YK,Kim JK,Kim MY,Rhim H,Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009;49 :453-459
16
Stang A,Fischbach R,Teichmann W,Bokemeyer C,Braumann D. A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer 2009;45 :1748-1756
17
Meloni MF,Andreano A,Laeseke PF,Livraghi T,Sironi S,Lee FT Jr. Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation—intermediate and long-term survival rates. Radiology 2009;253 :861-869
18
Fujii T,Takayasu K,Muramatsu Y,Moriyama N,Wakao F,Kosuge T, et al. Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol 1993;23:105–9.
[1] 诸佳玮, 陈强, 王辉阳, 蒋天安. 双极射频活检针在肝粗针活检止血的研发与初步应用[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(01): 69-74.
[2] 赵里汶, 贺需旗, 李凯. 虚拟导航辅助超声引导下经皮射频消融治疗直径≤2 cm肾上腺良性肿瘤的疗效研究[J/OL]. 中华医学超声杂志（电子版）, 2023, 20(12): 1282-1286.
[3] 杨建波, 马欢, 黄小梅, 刘华柱. 结肠镜辅助下EMR、CSP和RFA术治疗直径＜1cm结直肠息肉的疗效和安全性比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 76-79.
[4] 冯旺, 马振中, 汤林花. CT扫描三维重建在肝内胆管细胞癌腹腔镜肝切除术中的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 104-107.
[5] 林巧, 周丽. RFA联合LAH术治疗原发性肝癌并门静脉癌栓的临床效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 521-524.
[6] 张金华, 赵锁. 早期ICC腹腔镜肝切除术不同淋巴结清扫范围的近远期效果对比研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 578-581.
[7] 刘炯, 彭乐, 马伟, 江斌. 鞘外解剖肝蒂技术治疗肝内胆管细胞癌的疗效评估[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 373-376.
[8] 臧宇, 姚胜, 朱新勇, 戎世捧, 田智超. 低温等离子射频消融治疗腹壁疝术后补片感染的临床效果[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 687-692.
[9] 陆镜明, 韩大为, 任耀星, 黄天笑, 向俊西, 张谞丰, 吕毅, 王傅民. 基于术前影像组学的肝内胆管细胞癌淋巴结转移预测的系统性分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 852-858.
[10] 黄俊豪, 陈宗杰, 胡添松. 血小板相关参数对肝内胆管细胞癌根治性切除患者预后预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 308-312.
[11] 沈佳佳, 何经雄, 王芳, 江艺, 潘凡, 张小进. ICG荧光引导腹腔镜射频消融在合并严重大结节肝硬化小肝癌患者治疗中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(01): 68-71.
[12] 莫鹏, 郭杏春, 梁秀娟, 王耀明. 超声引导与CT引导射频消融治疗肝细胞癌患者疗效及预后比较[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(02): 151-154.
[13] 蒲丹, 龙煊, 周玉龙, 李甘霖. 血清外泌体miR-224对结直肠癌肝转移患者射频消融治疗后复发的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(01): 45-52.
[14] 陈轶维, 吴近近, 李奋, 孙彦隽, 郁夏风. 儿童左心耳起源房性心动过速镶嵌治疗一例[J/OL]. 中华心脏与心律电子杂志, 2024, 12(03): 185-188.
[15] 王楠钧, 马燕, 李隆松, 牛晓彤, 刘圣圳, 毕雅维, 苏松, 柴宁莉, 令狐恩强. 不同年龄段胃低级别上皮内瘤变患者内镜下射频消融术的疗效对比分析[J/OL]. 中华胃肠内镜电子杂志, 2024, 11(04): 238-242.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号

AI
小
编
AI小编
你好！我是《中华医学电子期刊资源库》AI小编，有什么可以帮您的吗？